NASDAQ: RLMDRelmada Therapeutics Inc Stock
$4.44-0.08 (-1.77%)
Updated Sep 14, 2026
RLMD Price
$4.44
Fair Value Price
$0.09
Market Cap
$473.61M
52 Week Low
$1.45
52 Week High
$8.00
P/E
-4.83x
P/B
2.29x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.93M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$46M
Beta
0.77
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RLMD Overview
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RLMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RLMD
Ranked#82 of 459
Ranked#82 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.14 | A | |
| $6.85 | A | |
| $41.54 | A |
Be the first to know about important RLMD news, forecast changes, insider trades & much more!
RLMD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RLMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RLMD ($4.44) is overvalued by 4,913.24% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RLMD ($4.44) is not significantly undervalued (4,913.24%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLMD due diligence checks available for Premium users.
Valuation
RLMD fair value
Fair Value of RLMD stock based on Discounted Cash Flow (DCF)
Price
$4.44
Fair Value
$0.09
Overvalued by
4,913.24%
RLMD ($4.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLMD ($4.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RLMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.83x
Industry
8.25x
Market
43.6x
RLMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.29x
Industry
5.35x
RLMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RLMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.9M
Profit Margin
0%
RLMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$219.1M
Liabilities
$12.5M
Debt to equity
0.06
RLMD's short-term assets ($219.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLMD's short-term assets ($219.04M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RLMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.6M
Investing
$17.6M
Financing
-$6.4M
RLMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RLMD vs Biotech Stocks
Relmada Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.